People who have Lung Problems report that their symptoms have decreased after taking an Nrf2 activator.  Following the testimonials are current research articles that report new information about the cause of Lung Problems and how Nrf2 activators can be effective in treating them at the cellular level where they start.

JB Moore:  I’ve been asthmatic for over 30 years. I have been using the nebuelizer 6 – 7 times a day to get relief. It’s a coincidence that I have not used the nebuelizer for 3 months and the inhaler I have only used about 3 times in 3 months. Thank you ASEA!!!!  (

Mark:  Hi, I have been a smoker for more than 20 years now, and after suffering from several bronchial infections and a bout of pneumonia since the beginning of the year, my doctor told me that I was very close to getting COPD. Since then, I have been working on quitting. Following the advice of the pulmonologist, I bought the NRF 2 Activator as a means to help my body and especially my lungs flush away and clean out all the harmful toxins which have piled up there from the smoking as well as any bacteria left over from my earlier infections. Now, I have thrown away the cigarettes and am breathing freely, feeling better than ever! I think that I will continue taking the NRF 2 Activator because it makes me feel healthy and young again.  (
Sandra Norris: “For the last 21 years I have struggled with a debilitating health issue that among other things has weakened my immune system. This winter there was a nasty respiratory illness that went through our community and my family was hit hard. Usually I am the first to get sick and the last to recover; many years I suffer with bronchitis. For weeks, as my family all came down with it, recovered, and then were sick again I was amazed that my immune system was able to keep me from "catching" this illness. Wow... For the first winter, in as long as I can remember, I have not been sick with a respiratory illness or flu.”


Eur Respir J. 2015 Jan 22. pii: ERJ-02297-2014. [Epub ahead of print]

Mechanisms of development of multimorbidity in the elderly.

Barnes PJ1.

Author information Abstract

In ageing populations many patients have multiple diseases characterised by acceleration of the normal ageing process. Better understanding of the signalling pathways and cellular events involved in ageing shows that these are characteristic of many chronic degenerative diseases, such as chronic obstructive pulmonary disease (COPD), chronic cardiovascular and metabolic diseases, and neurodegeneration. Common mechanisms have now been identified in these diseases, which show evidence of cellular senescence with telomere shortening, activation of PI3K-AKT-mTOR signalling, impaired autophagy, mitochondrial dysfunction, stem cell exhaustion, epigenetic changes, abnormal microRNA profiles, immunosenescence and low grade chronic inflammation ("inflammaging"). Many of these pathways are driven by chronic oxidative stress. There is also a reduction in anti-ageing molecules, such as sirtuins and Klotho, which further accelerates the ageing process. Understanding these molecular mechanisms has identified several novel therapeutic targets and several drugs have already been developed that may slow the ageing process, as well as lifestyle interventions, such as diet and physical activity. This indicates that in the future new treatment approaches may target the common pathways involved in multimorbidity and this area of research should be given high priority. Thus, COPD should be considered as a component of multimorbidity and common disease pathways, particularly accelerated ageing, should be targeted.

[INTERPRETATION:  Scientists understand the disease pathways better now, and how they are the same for aging and many diseases including COPD.  Oxidative stress (cell destruction) causes swelling and poor immunity, which then leads to disease.  New therapies and drugs have been developed that target oxidative stress, so they fix many different problems at once, including COPD.]


Int J Chron Obstruct Pulmon Dis. 2015 Feb 2;10:261-276.

COPD: balancing oxidants and antioxidants.

Fischer BM1, Voynow JA2, Ghio AJ3.

Author information Abstract

Chronic obstructive pulmonary disease (COPD) is one of the most common chronic illnesses in the world. The disease encompasses emphysema, chronic bronchitis, and small airway obstruction and can be caused by environmental exposures, primarily cigarette smoking. Since only a small subset of smokers develop COPD, it is believed that host factors interact with the environment to increase the propensity to develop disease. The major pathogenic factors causing disease include infection and inflammation, protease and antiprotease imbalance, and oxidative stress overwhelming antioxidant defenses. In this review, we will discuss the major environmental and host sources for oxidative stress; discuss how oxidative stress regulates chronic bronchitis; review the latest information on genetic predisposition to COPD, specifically focusing on oxidant/antioxidant imbalance; and review future antioxidant therapeutic options for COPD. The complexity of COPD will necessitate a multi-target therapeutic approach. It is likely that antioxidant supplementation and dietary antioxidants will have a place in these future combination therapies.

PMID: 25673984  [PubMed - as supplied by publisher]

 [INTERPRETATION:  The cause of COPD is infection, inflammation, chemical imbalance, and oxidative stress (cell damage by oxidants).  Future treatments will be reduce the oxidative stress by use of antioxidants.]